Enzolytics, Inc. (ENZC)
OTCMKTS · Delayed Price · Currency is USD
0.0006
0.00 (0.00%)
At close: Jan 23, 2026
Enzolytics Revenue
Enzolytics had revenue of $46.59K in the twelve months ending March 31, 2012, up 26.03% year-over-year. In the year 2011, Enzolytics had annual revenue of $52.81K with 42.85% growth.
Revenue (ttm)
46.59K
Revenue Growth
+26.03%
P/S Ratio
62.22
Revenue / Employee
n/a
Employees
3
Market Cap
2.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2011 | 52.81K | 15.84K | 42.85% |
| Dec 31, 2010 | 36.97K | 22.26K | 151.35% |
| Dec 31, 2009 | 14.71K | 9.02K | 158.62% |
| Dec 31, 2008 | 5.69K | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sorrento Therapeutics | 64.27M |
| Carisma Therapeutics | 52.63M |
| Vaccinex | 601.00K |
| AXIM Biotechnologies | 92.90K |
| Enzon Pharmaceuticals | 26.00K |
Enzolytics News
- 1 year ago - Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator - Accesswire
- 1 year ago - Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement - Accesswire
- 1 year ago - Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells - Accesswire
- 1 year ago - Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications - Accesswire
- 1 year ago - Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. - Accesswire
- 1 year ago - Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release - Accesswire
- 1 year ago - Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment - Accesswire
- 1 year ago - Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology - Accesswire